Description:
Tofacitinib is an orally available JAK3 inhibitor (IC50 = 1 nM), exhibiting 20- and 100-fold less potency against JAK2 and JAK1. Tofacitinib induces G1 cell cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. It is approved for the treatment of rheumatoid arthritis (RA).
- Molecular Weight: 312.37
- Molecular Formula: C16H20N6O
Purity: >98%
Canonical SMILES:
CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N
InChI:
InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1
InChIKey: UJLAWZDWDVHWOW-YPMHNXCESA-N
Synonyms:
Tasocitinib; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550
More details are to be found on supplier website
